Business Context and Reporting Period
PharmaCyte Biotech, Inc. (PMCB) filed a Form 8-K on May 20, 2024, reporting the entry into a Material Definitive Agreement with MyMD Pharmaceuticals, Inc. ("MyMD"). The transaction involves a strategic investment by PharmaCyte into MyMD, with the closing expected on May 23, 2024.
Key Financial Metrics and Transaction Terms
This filing details a specific investment transaction rather than periodic financial performance. Key metrics include:
- Total Purchase Price: $7,000,000.
- Assets Acquired:
- Series G Convertible Preferred Stock (convertible into 3,854,626 MyMD common shares).
- Long-Term Warrants to purchase 3,854,626 shares (5-year term).
- Short-Term Warrants to purchase 3,854,626 shares (18-month term).
- Conversion/Exercise Price: $1.816 per share (subject to full ratchet adjustments).
- Dividend Rate: 10% per annum, compounded monthly (payable in cash or shares); increases to 15% upon a "Triggering Event."
- Voting Rights: As-converted basis calculated at $2.253 per share.
Material Changes and Strategic Implications
The filing represents a material change in PharmaCyte's investment portfolio and corporate relationships. Key strategic elements include:
- Board Representation: PharmaCyte has the right to nominate one individual to MyMD's board of directors until its beneficial ownership falls below 20% on an as-converted basis.
- Future Participation: PharmaCyte retains the right to participate in future equity sales by MyMD until the second anniversary of the closing or until no Preferred Shares remain outstanding.
- Liquidity Provisions: MyMD agreed to establish a 10b5-1 sales program for PharmaCyte's shares and file a resale registration statement covering 200% of the conversion and warrant shares within 30 days of closing.
Guidance, Risks, and Contingencies
The filing outlines specific contingencies and risks associated with the investment structure:
- Triggering Events: Defined events include MyMD's failure to file/maintain an effective registration statement or failure to pay amounts due. Upon such events, PharmaCyte can require a cash redemption of Preferred Shares at a premium.
- Redemption Rights: MyMD has the option to redeem Preferred Shares in cash at a premium at any time after issuance.
- Covenants: MyMD is subject to affirmative and negative covenants regarding indebtedness, liens, asset transfers, and distributions.
- Financial Reporting: Pro forma financial information is required to be filed within 71 days of this report.
Investor Verification Checklist
- Verify the closing of the transaction on or around May 23, 2024.
- Review the filed Certificate of Designations (Exhibit 10.2) for specific redemption premium calculations and "Triggering Event" definitions.
- Monitor the filing of the resale registration statement by MyMD within 30 days of closing.
- Assess the impact of the $7 million cash outflow on PharmaCyte's current liquidity position.
- Check for the appointment of the nominated director to MyMD's board.